Celiac disease: New therapies on the horizon.

Tessa Dieckman, Frits Koning, Gerd Bouma

Journal: Current opinion in pharmacology 2022;66():102268

PMID: 35921776

Free Full Text on Elsevier Science View on PubMed

Abstract

Celiac Disease (CeD) is a chronic intestinal disease which occurs in 0.7-1.4% of the global population. Since the discovery of gluten as its disease-inducing antigen, CeD patients are treated with a gluten-free diet which is effective but has limitations for certain groups of patients. Accordingly, over the past few years, there is a growing interest in alternative treatment options. This review summarizes emerging pharmacological approaches, including tolerance induction strategies, tissue transglutaminase inhibition, gluten degradation, and inhibition of interleukin (IL)-15.

Address: Department of Gastroenterology and Hepatology, Amsterdam UMC, location VU Medical Center, AGEM Research Institute, Amsterdam, the Netherlands; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Gastroenterology and Hepatology, Amsterdam UMC, location VU Medical Center, AGEM Research Institute, Amsterdam, the Netherlands. Electronic address: [email protected].

DOI: 10.1016/j.coph.2022.102268